According to Zhitong Finance App News, Conoa-B (02162.HK) announced that the company's product Kangyueda® (IL-4Rα monoclonal antibody, spiqibizumab) achieved total revenue of about RMB 660 million in the first three quarters of 2026, an increase of about 227% over the previous year. The core driver came from actual market demand and a sharp increase in the number of admitted hospitals. Thanks to national policy support, Kangyueda® has been approved for marketing in adults since January 1, 2026 for the three indications of severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps (CRSwnP), and seasonal allergic rhinitis (SAR), and two types of vials and pre-filled automatic pens The packages have all been included in China's national medical insurance drug catalogue. The medical insurance payment standard is RMB 1,039 per bottle (specification is 300 mg/2 ml), which greatly enhances affordability for Chinese patients. Meanwhile, in July 2026, Kangyueda® was officially included in the “National Essential Drug Catalogue (2026 Edition)”, which will take effect from September 1, 2026. According to the relevant regulations on basic drugs, public medical institutions at all levels across the country must equip and prioritize the use of drugs in the catalogue as required, further broaden terminal prescription scenarios, and enhance drug accessibility.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.